The enhanced understanding about the biology of cancer has shown that cancer is driven by a wide variety of clinically actionable alterations. An increase in the adoption of more comprehensive, clinical-grade sequencing platforms later promoted recognition in the presence of targetable genomic alterations across multiple tumor types. Increasing cancer incidences and need for more targeted therapy has led to identification of tropomyosin receptor kinases (TRK).
Tropomyosin receptor kinases A, B, and C (TRKA, TRKB, and TRKC) belong to cell surface receptor tyrosine kinases family and are encoded by the neutrotrophic receptor tyrosine kinase 1, 2, and 3 (NTRK1, NTRK2, and NTRK3) gene respectively. The TRK have shown to play a vital role in physiology, development, and function of the peripheral and central nervous systems. In addition, the activation of TRK triggers a cascade of signaling pathways including MAPK, P13K, and PLCy which have critical role in the cell proliferation, survival, and angiogenesis.
Global TRK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global TRK Inhibitors Market Opportunity Assessment: > USD 2 Billion
- Market & Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 Drugs
- Approved TRK Drug Patent, Price & Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Further, research studies have shown that alterations in NTRK gene is found in majority of rare cancers including infantile fibrosarcoma, secretory carcinoma of breast and salivary glands, and others. In addition, NTRK gene fusions are also identified at lower frequencies in common cancers including non-small cell lung cancer, breast cancer, colorectal cancer, thyroid cancer, and others. Therefore, these fusions have emerged out to be important anti-tumor targets and considerable efforts have been done by researchers to design drugs which can inhibit their activity as an alternative for cancer management.
Vitrakvi (Larlotrectinib) developed by Loxo Oncology was the first TRK inhibitor approved. The drug was granted approval by US FDA in 2018 and is indicated for the treatment of adult and pediatric patients with solid tumors that have NTRK gene fusion without a known acquired resistance mutation are metastatic or where surgical resection is likely to result in severe morbidity and have no satisfactory alternative treatments or that have progressed following treatment. Following this, the drug has subsequently gained approval in other regions also.
Later, Genentech developed another TRK and anaplastic lymphoma kinase inhibitor which showed potential anti-tumor activity. Rozlytrek (Entrectinib) was granted approval in 2019 for the treatment of adult patients with non-small cell lung cancer. Furthermore, the drug was also approved for the management of adult and pediatric patients 12 years of age and older with NTRK positive solid tumors.
Since their entry into the market, these drugs have shown high penetration rates owing to their targeted nature. Their robust response has initiated several research and development activities by researchers which have led to the development of robust pipeline of drugs which are expected to enter the market in coming years. The potential next generation TRK inhibitors in pipeline are including Selitrectinib, IC723, or CHC2014. These have shown to overcome the limitations of first generation TRK inhibitors and are expected to enter the market during forecast period.
Currently, the researchers are evaluating the role of approved TRK inhibitors in other NTRK positive cancers which will further propel the growth of market. Apart from this, researchers are also evaluating the role of first generation TRK inhibitor in combination with other cancer targeting regimens including immunotherapeutic drugs, chemotherapeutic agents, and other small molecule targeting drugs. The combinational therapy combined two or more molecules which have synergistic activity, thus enhancing its efficacy in the management of cancer cell.
The major key players working in global TRK inhibitor market are Roche, AstraZeneca, Pfizer, Eli Lilly, Turning Point, and Loxo Oncology. These pharmaceutical giants have adopted strategic alliances including collaboration, partnerships, or joint ventures. The strategic alliances allow companies to share risks and rewards as well as offer opportunity to utilize each other novel technologies. For instance in May, 2021 AUM Biosciences have entered into strategic collaboration with Handok Inc. and CMG Pharmaceutical for the worldwide (excluding Korea) development, commercialization, and manufacturing rights of CHC2014, which is highly specific and efficacious pan-TRK inhibitor.
Currently, the global TRK inhibitor market is small due to approval of two products only. However, it is expected that in forthcoming years, market will witness high growth rates owing to rapid approval of next generation TRK inhibitors and extended approval in other therapeutic conditions. In addition, coming years will witness increase in prevalence of cancer which will increase the demand of targeted therapy, thus boosting the growth of market.
US is expected to maintain a significant share in the global TRK inhibitor market owing to predominant sales of approved drugs in the region. Apart from drug approvals, the pharmaceutical companies in US have also developed several favorable reimbursement policies to ensure the uptake of drugs in the market. For instance, US government has developed Vitrakvi Co-pay program and Rozlytrek Co-pay program for help with out of pocket cost associated with the drugs. These policies reduce financial toxicity on patients and help in greater adoption of the drugs by patients in US. In addition, Europe region is likely to drive the market during the forecast period owing to increase in prevalence of cancer and developed healthcare facilities. The rest of the world like India, Middle East, and other regions are also anticipated to grow at fast rates owing to various initiatives to aware, educate people, and raise funds for the cancer.